The text discusses the findings and implications of using FES PET (Fluoroestradiol Positron Emission Tomography) in oncology, particularly concerning treatment decisions for cancer patients.
-
Imaging Findings: Preliminary data indicates that FES PET has revealed additional lesions in some patients, which altered their treatment paths. This highlights FES PET’s potential in identifying estrogen receptor activity in lesions that conventional imaging may overlook.
-
Systemic Therapy: Bazan warns that findings regarding systemic therapy are still preliminary, with some patients on stable treatment for six months. However, better methods are needed to differentiate between slight progression and broader resistance to treatment. The study also looks at circulating tumor DNA to enhance information gleaned from imaging.
-
Role of Pharmacists: The text emphasizes the significance of oncologists and pharmacists coordinating medication management. This is especially pertinent given the variable effectiveness of treatment combinations, such as SBRT and systemic therapies, particularly with certain CDK4/6 inhibitors and newer oral selective estrogen receptor degraders.
-
Medication Review: Prior to FES PET, it’s crucial to review medications that may affect estrogen receptor binding, necessitating careful planning to ensure accurate imaging and maintain continuity in cancer care. Pharmacists play a key role in this process.
Overall, the text underscores the potential of FES PET in refining treatment decisions while also highlighting the complex interplay between various therapies and their implications for patient management.
